Overview

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Cystic Fibrosis (CF) and if so how it compares to placebo (a substance which does not have any action).
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca